Abstract
Drug therapy is the primary treatment for patients with advanced cancer. The use of anticancer drugs will inevitably lead to drug resistance, which manifests as tumor recurrence. Overcoming chemoresistance may enable cancer patients to have better therapeutic effects. However, the mechanisms underlying drug resistance are poorly understood. E3 ubiquitin ligases (E3s) are a large class of proteins, and there are over 800 putative functional E3s. E3s play a crucial role in substrate recognition and catalyze the final step of ubiquitin transfer to specific substrate proteins. The diversity of the set of substrates contributes to the diverse functions of E3s, indicating that E3s could be desirable drug targets. The E3s MDM2, FBWX7, and SKP2 have been well studied and have shown a relationship with drug resistance. Strategies targeting E3s to combat drug resistance include interfering with their activators, degrading the E3s themselves and influencing the interaction between E3s and their substrates. Research on E3s has led to the discovery of possible therapeutic methods to overcome the challenging clinical situation imposed by drug resistance. In this article, we summarize the role of E3s in cancer drug resistance from the perspective of drug class.
Introduction
Cancer is a multifactorial disease and is considered the most severe public health issue worldwide (Siegel et al., 2019). Drug therapy is the main treatment for patients with advanced cancer. The drugs currently used for tumor treatment include platinum drugs, antitumor antibiotics, alkylating agents, hormones, molecular targeting agents, and immunotherapy. The use of tumor drugs will inevitably lead to drug resistance, which manifests as tumor recurrence (Glickman and Sawyers, 2012; Vasan et al., 2019).
Several mechanisms have been found to underlie anticancer drug resistance, including the effects of cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), and DNA damage repair (DDR) (Gong et al., 2018). Identifying the key molecules in these processes can help us understand the occurrence of drug resistance, and these key molecules play an essential role in predicting and reversing resistance to anticancer drugs. However, the mechanisms have not yet been elucidated.
Ubiquitination and E3 Ubiquitin Ligases
Protein ubiquitination-based modification can regulate various signal-mediated cell death responses and plays an essential role in the occurrence, development, and outcome of cancer (Nalepa et al., 2006). Ubiquitination refers to the process by which ubiquitin is covalently bound to target proteins under the catalysis of a series of enzymes. The ubiquitination process usually requires the cooperation of the E1 ubiquitin-activating enzymes (E1s), E2 ubiquitin-coupling enzymes (E2s), and E3 ubiquitin ligases (E3s) (Buetow and Huang, 2016). Mechanistically, ubiquitin is activated in an ATP-dependent manner, inducing a thioester bond with an E1. The moieties are then transferred to the active site cysteine of the E2. The E3 binds to both the E2∼Ub thioester and the substrate, catalyzing the transfer of ubiquitin from the active site cysteine of the E2 to the substrate lysine or N terminus (Tatham et al., 2013; Berndsen and Wolberger, 2014).
Ubiquitin chain topology determines the fate of ubiquitylated proteins (Ikeda and Dikic, 2008). Usually, ubiquitin-dependent proteolysis is associated with K48-linked and K11-linked ubiquitin chains. However, activation of signaling pathways is mainly dependent on K63‐linked or M1-linked ubiquitin chains. Ubiquitin-mediated proteolysis is essential for the maintenance of protein homeostasis because it removes misfolded or unwanted proteins. The non-proteasomal ubiquitin-mediated assembly of signaling complexes also plays a pivotal role in several cellular processes, such as autophagy, DNA repair, and endocytosis (Bennett and Harper, 2008; Chen and Sun, 2009; Cappadocia and Lima, 2018). Given these phenomena, it is understandable that the dysregulation of ubiquitination can lead to genetic and epigenetic alterations in cancer.
E3s are critical components in the ubiquitination reaction owing to their strict control of both substrate affinity and specificity (Zheng and Shabek, 2017). E3s are a large class of proteins, and there are over 800 putative functional E3s (Ciechanover, 2015). E3s have been classified into three subgroups: E3s containing really interesting new gene (RING) and UFD2 homology (U-box) domains, the 28-member homologous to E6AP carboxyl terminus (HECT) E3 family, and the 14‐member RING‐between‐RING (RBR) E3 family (Uchida and Kitagawa, 2016). The diversity of the E3 substrates contributes to the diverse functions of E3s (Li et al., 2014), and as a result, E3s are closely related to tumorigenesis because they regulate oncogenes and tumor suppressors (Senft et al., 2018). In addition, the substrate specificity of E3s suggests that they have promise as anticancer drug targets (Wang et al., 2017). Here, for the first time, we summarize the role of E3s in anticancer drug resistance from the perspective of drug class (Figure 1).
FIGURE 1
Platinum Drugs
Platinum drugs are widely used in the treatment of human cancers. The zinc-finger E3s MUL1 and UBR5 was found to be involved in platinum resistance. The E3 UBR5 was amplified and overexpressed in ovarian cancer (OC). Higher UBR5 expression was observed in platinum-resistant OC tumor tissue than in normal tissues. Overexpression of UBR5 induced cisplatin resistance in OC cells both in vivo and in vitro. Moreover, UBR5 knockdown via siRNA partly reversed platinum resistance in OC cells (O'Brien et al., 2008; Bradley et al., 2014). Mitochondrial E3 ubiquitin-protein ligase 1 (MUL1) is an E3 that interacts with and negatively regulates AKT. The degradation of AKT was found to lead to cisplatin sensitivity in OC cells (Lee et al., 2019). A decrease in EMT in cisplatin-resistant nasopharyngeal carcinoma (NPC) cells was observed after upregulation of NEDD4 in cells, suggesting that NEDD4 could be a novel therapeutic target for overcoming drug resistance in NPC (Feng et al., 2017).
Tripartite motif (TRIM) family proteins, most of which have E3 activities, control important cellular processes such as intracellular signaling, innate immunity, transcription, autophagy, and carcinogenesis (Hatakeyama, 2017). TRIM25 expression was identified to be significantly lower in the cisplatin-resistant non-small cell lung carcer (NSCLC) cell line A549 than in control cell lines (Qin et al., 2012). Overexpression of TRIM32 promoted degradation of Abi2, resulting in enhancement of cell growth, transforming activity, and cell motility. Moreover, TRIM32 suppressed the apoptosis induced by cisplatin in the hepatocellular carcinoma (HCC) cell line HEp2. Overexpression of TRIM32 in the HCC cell line also induced resistance to another platinum drug, oxaliplatin (Cui et al., 2016). Increased TRIM11 expression inhibits the apoptosis induced by cisplatin, and TRIM11 functions as an oncogene related to drug resistance both in vivo and in vitro. TRIM11 destabilized Daple in a p62-selective autophagic manner, further upregulating β-catenin expression to induce enhanced expression of ABCC9, which can transport chemotherapeutic drugs (Zhang et al., 2020). Autophagy can be a key mechanism of resistance to chemotherapy (Onorati et al., 2018). TRIM65 was found to be upregulated in NSCLC, and its overexpression promoted NSCLC cell resistance to cisplatin (Li et al., 2016). The inhibition of miR-138–5p attenuated the effects of TRIM65 knockdown on autophagy and cisplatin-induced apoptosis, suggesting that TRIM65 regulates cisplatin resistance in NSCLC by regulating miR-138–5p (Pan et al., 2019). TRIM59 was also found to be overexpressed in cisplatin-resistant A549 cells, and its overexpression in these cells resulted in increased cisplatin resistance. TRIM59 enhanced the ubiquitination of PTEN, a critical upstream regulator of HK2. The regulation of the PTEN/AKT/HK2 pathway induced by TRIM59 might provide insights into overcoming cancer resistance to cisplatin treatment (He and Liu, 2020).
Another type of RING-box-containing E3s, RING finger proteins (RNFs), play a role in platinum resistance. RNF38 was proposed as a biomarker of poor NSCLC prognosis, and its silencing increased the sensitivity of NSCLC cells to cisplatin (Wu et al., 2020). RNF138 was more highly expressed in cisplatin-resistant gastric cancer (GC) cell lines than in normal cell lines and modulated cisplatin resistance in these GC cells (Lu et al., 2018). Pellino family proteins (Pellino-1, 2, and 3) are E3s that contain C-terminal RING-like domains. Pellino-1 overexpression conferred NSCLC cells with resistance to the apoptosis induced by cisplatin or paclitaxel (Jeon et al., 2016).
The F-box-containing family member FBXW7 is one of the four subunits of the SKP1-cullin-F-box (SCF)-E3 complex, which functions in phosphorylation-dependent ubiquitination (Skaar et al., 2014). In NSCLC, FBXW7 upregulation significantly increased cisplatin chemosensitivity and abrogated the mesenchymal phenotype of NSCLC cell lines (Yu et al., 2013). Another report by Guodong X et al. indicated that FBXW7 could interact with Snai1 in NSCLC cell lines and directly degrade its expression, resulting in suppression of cisplatin and sorafenib resistance (Guodong et al., 2018). In colorectal carcinoma (CRC) cells, FBXW7 deficiency induced by mutation or loss can lead to the aberrant phosphorylation of p53 at serine 15 and further promote resistance to oxaliplatin. An understanding of the regulation of phospho-p53 (Ser15) by FBXW7 E3 activity could provide important clues for the clinical targetability of this axis (Perez-Losada et al., 2005; Li et al., 2015). In NPC, upregulation of FBXW7 significantly increased cisplatin-based chemosensitivity (Song et al., 2015). The CRL4 expression level was increased in cisplatin-resistant OC cells. CRL4 knockdown with shRNAs was able to reverse the cisplatin resistance of OC cells (Hu et al., 2019). In CRC, knockdown of CUL4A sensitized parental CRC cells to cisplatin (Englinger et al., 2017). CUL4B destabilized HP1α, a gene that suppresses the open confirmation of chromatin that is important for the DDR and DNA repair. The DDR and DNA repair are believed to be reasons for cisplatin resistance (Kim et al., 2017).
F-box-only proteins are the substrate-recognition component of the SCF-E3 complex. The relatively low level of FBXO22 in A549 cells contributes to an accumulation of CD147 and the cisplatin resistance of the cells (Wu et al., 2017). Additionally, FBXO21 was found to ubiquitinate and destabilized P-glycoprotein (P-gp), resulting in attenuation of multidrug resistance. However, a stem cell marker, CD44, was found to inhibit FBXO21-directed degradation of P-gp and promote multidrug resistance (Ravindranath et al., 2015). Using a microarray, another E3, FBXO32, was newly identified as a negative regulator of EMT in urothelial carcinoma (UC) tumors after they had acquired platinum resistance. FBXO32 dysregulation in platinum-resistant UC cells resulted in elevated expression of the EMT marker snail and decreased expression of E-cadherin (Tanaka et al., 2016).
SKP2, also known as F-box and leucine-rich repeat protein (FBXL1), is a member of the FBXL subfamily of F-box proteins and plays a pivotal role in cell cycle progression and proliferation. Evidence has shown that SKP2 can interact with Akt and facilitate its ubiquitination. K63-mediated AKT ubiquitination can be mediated by Skp2 and can regulate NPC to induce cisplatin resistance (Yu et al., 2019). Overexpression of SKP2 reduced the expression of p27Kip1, cyclin E, and p21Cip1, increased the proportion of S-phase cells, and increased resistance against cisplatin in NSCLC cell lines (Ishii et al., 2004).
E3s targeting P53 play a role in cisplatin resistance. MDM2, an important regulator of P53, controls cisplatin resistance in multiple cancers. MDM2 interacted and destabilized P53 and induced tumor cell resistance to cisplatin (Muscolini et al., 2011; Sheng et al., 2017). The genes encoding molecules that interfere with the interaction between MDM2 and p53 might also lead to drug resistance. Some genes, such as zinc-finger CCHC-type containing 10 (ZCCHC10) and NUMB, inhibit cisplatin resistance by interfering with P53 ubiquitination mediated by MDM2 (Colaluca et al., 2008; Ning et al., 2019). TRAF6, an E3 that controls p53 mitochondrial translocation, was found to be overexpressed in CRC tissues. TRAF6 overexpression negatively correlates with apoptosis and predicts poor response to cisplatin-based chemotherapy and radiotherapy (Zhang et al., 2016). Cisplatin can enhance the FLIP-p53-Itch interaction, inducing FLIP ubiquitination and degradation in a p53-and Itch-dependent manner. These results suggest that the modulation of FLIP content may be an effective strategy for overcoming chemoresistance in OC (Abedini et al., 2008; Abedini et al., 2010).
The U-box domain-containing E3 CHIP has been studied to help understand drug sensitivity. CHIP knockdown increases the proportion of cisplatin-sensitive cells. CHIP can act as an activator of Bcl-2 expression levels to suppress breast cancer (BC) malignant progression (Tsuchiya et al., 2015). In addition to CHIP’s role in BC, Dong‐E Tang et al. revealed that CHIP could ubiquitinate YAP1 at the K280 site by K48‐linked polyubiquitination and also generated a human GC cell line with resistance to cisplatin resistance (Tang et al., 2019). Microtubule-associated serine/threonine kinase 1 (MAST1) mediates cisplatin resistance in human cancers. Pan C et al. used a proteomics screen to identify CHIP-destabilized MAST1. The MAST1 destabilization resulted in hsp90B-induced sensitivity to cisplatin (Pan et al., 2019). ZFP91 knockdown reduced FOXA1 polyubiquitination, which decreased FOXA1 turnover and enhanced cellular sensitivity to cisplatin therapy (Tang et al., 2020). E3s and their corresponding substrates are summarized in Figure 2.
FIGURE 2
Drugs Derived From Plants
Paclitaxel is an M-phase-specific plant drug initially derived from the Pacific yew and has become the first member of the taxane family to be used in cancer chemotherapy (Bernabeu et al., 2017). In a single-cell RNA sequencing analysis, protein ubiquitination was identified as the most differentially regulated pathway in docetaxel-resistant prostate cancer (PC) cells (Schnepp et al., 2020).
In NSCLC, BC and GC, silencing FBXW7 resulted in enhanced Taxol resistance (Yokobori et al., 2014; Gasca et al., 2016). However, in dormant BC cells, disruption of FBXW7 resulted in a shift of tumor cells from the quiescent state, rendering them susceptible to chemotherapy (Shimizu et al., 2019). miR-363 expression can promote chemoresistance by directly targeting FBXW7 (Zhang et al., 2016). Another Fox-containing E3, FBXW11, was also found to be involved in the development of Taxol resistance via associations with FOXO3a (Su et al., 2011). In PC, Skp2 silencing or using Skp2 inhibitors restored paclitaxel sensitivity in paclitaxel-resistant PC cells (Yang et al., 2016). EDD, an E3, promotes docetaxel resistance in hormone-refractory PC by regulating Wnt/β-Catenin signaling (Bian et al., 2020). In PC, SPOP knockout was found to confer resistance to cell death caused by docetaxel (Shi et al., 2019). Taxol decreased the expression of HDAC3 while increasing the expression of SIAH2 in melanoma cells. In addition, the E3 ligase SIAH2 can interact with HDAC3 and by so doing confers resistance to Taxol (Kim et al., 2015).
E3s targeting p53 also play roles in Taxol resistance. Pirh2, a RING finger-containing E3, can lead to polyubiquitination and proteasomal degradation of p53. The ectopic expression of Pirh2 enhanced cell proliferation, resistance to doxorubicin, and migration potential (Daks et al., 2016). The protease HAUSP is a critical component of the p53-Mdm2 pathway and acts as a specific deubiquitinase for p53 and Mdm2 and is thus essential for p53 regulation. HAUSP downregulation causes resistance to another plant-derived drug, camptothecin, and camptothecin-induced apoptosis (Becker et al., 2008). Parkin interferes with paclitaxel-induced microtubule assembly and stabilization by directly binding the microtubules on the outer cell surface. In addition, Parkin promotes the activity of paclitaxel to trigger multinucleation and apoptosis. Moreover, clinical data have revealed that the response of patients to preoperative paclitaxel therapy is correlated with Parkin expression (Wang et al., 2009).
Antimetabolite Drugs
Fludarabine is a DNA synthesis inhibitor (Lukenbill and Kalaycio, 2013). In vitro and in vivo experiments showed that COP1 overexpression reduced HG3 cell sensitivity to fludarabine treatment by promoting ubiquitin-dependent p53 degradation (Fu et al., 2018). This result indicates that E3s promoting P53 degradation can also be related to fludarabine resistance.
5-Fluorouracil (5-FU) inhibits thymidylate synthase from activating thymine-induced cell death and functions mainly as an S-phase antimetabolite (Longley et al., 2003). In BC, high preoperative expression of Skp2 was found to be associated with resistance to 5-FU therapy in 94% of patients (Davidovich et al., 2008). Cbl was decreased in 60% of human pancreatic ductal adenocarcinoma (PDAC) cases. Cbl knockdown increased PDAC resistance to gemcitabine and 5-FU (Kadera et al., 2015). TRIM47 is commonly overexpressed and related to poor prognosis in CRC patients. TRIM47 increases the ubiquitination and degradation of SMAD4. The overexpression of TRIM47 elevated CRC chemoresistance in response to 5-FU therapy (Liang et al., 2019). In CRC, high FBXW7 expression downregulated CRY2 through proteasomal degradation and increased CRC cell sensitivity to 5-FU (Fang et al., 2015). Cancer-associated fibroblasts (CAFs) play a pivotal role in creating the tumor microenvironment, which impacts adaptive resistance to chemotherapy (Kalluri, 2016). CRC cells cocultured with CAFs showed increased expression of RANBP2-type and C3HC4-type zinc-finger-containing 1 (RBCK1). Additionally, overexpression of RBCK1 was demonstrated in chemoresistant CRC tumors and CRC patients with poor prognosis. Exogenous expression of RBCK1 or RBCK1 inhibition was able to significantly influence 5-FU sensitivity in CRC cells (Liu et al., 2019).
Gemcitabine is another widely used S-phase antimetabolite drug (Mini et al., 2006). In pancreatic cancer (PCC) cells, FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) through lysosome inhibition (Hu et al., 2017). SMURF2 was downregulated in PCC tissues, and its expression was negatively associated with gemcitabine resistance. Upregulation of miR-15b was associated with degradation of SMURF2, and its expression was associated with EMT (Zhang et al., 2015). TRIM31 overexpression conferred gemcitabine resistance to PCC cells by promoting K63-linked polyubiquitination of tumor necrosis factor receptor-associated factor 2 (TRAF2) and sustained the activation of nuclear transcription factor kappa B (NF-κB) in PCC cells (Yu et al., 2018). Cul4A degraded TGFβ1, and its overexpression promoted resistance to gemcitabine in lung cancer. In vivo experiments, Cul4A-RNAi combined with gemcitabine chemotherapy inhibited lung cancer tumor growth, suggesting that this combination may provide a new approach for lung cancer treatment (Hung et al., 2015).
Asparaginase is a drug that selectively inhibits tumor cells by hydrolyzing asparagine (Asselin and Rizzari, 2015). FBXW7 overexpression can rescue Wnt-induced sensitization to asparaginase in FBXW7 mutant or wild-type leukaemias. In contrast, the FBXW7 R465C mutant, which has impaired binding to its canonical phosphodegron, abrogated this effect (Hinze et al., 2019).
Alkylating Agents
Among various antitumour drugs, alkylating agents may be the most widely used category (Bhatt et al., 2017). Alkylating agents are cytotoxic drugs that combine with cell proteins and nucleic acids to kill tumor cells and have a direct toxic effect on cells (Lajous et al., 2019). Temozolomide (TMZ) is a DNA alkylating agent that can penetrate the blood-brain barrier. HERC3, an E3, promotes the ubiquitination-mediated degradation of SMAD7 and consequently activates the TGF-β pathway. Moreover, ectopic HERC3 expression was correlated with TMZ resistance in glioblastoma (GBM) cells (Li et al., 2019). Nucleolin (NCL) is overexpressed in GBM, and its overexpression was found to be positively relative to response to TMZ in GBM cells. The loss of MDM2-mediated NCL ubiquitination resulted in the inhibition of HDAC activity and sensitized GBM cells to TMZ (Ko et al., 2018).
Anticancer Antibiotics
Doxorubicin is a cytotoxic anthracycline antibiotic that is often used as a tumor chemotherapy agent. Using mass spectrometry analysis, Kamran M et al. found that AURKA restricted FBXL7-induced survivin ubiquitination and degradation in GC, resulting in the promotion of doxorubicin resistance (Kamran et al., 2017). Doxorubicin-resistant HCC cells showed decreased expression of FBXW7. HSF1 was found to play an essential role in transcriptional activation of MDR1 via FBXW7-mediated degradation (Mun et al., 2020). Expression of P-gp on cancer cell surfaces is a critical determinant of anticancer drug resistance (Lin and Yamazaki, 2003). In other words, the reversal of drug resistance can be achieved by modulating the ubiquitination of P-gp (Zhang et al., 2004). Via mass spectrometry analyses, FBXO15/Fbx15 was found to interact with P-gp (Katayama et al., 2013). The downregulation of P-gp expression by UBE2R1-and FBXO15-mediated ubiquitination boosted sensitivity to vincristine and doxorubicin (Katayama et al., 2016).
Zeb1, an influential EMT-related transcription factor, mediated cell resistance to doxorubicin treatment. In HCC doxorubicin-resistant cells, the downregulation of SIAH1 mediated the stability of Zeb1, aiding resensitization of cells to doxorubicin treatment (Long et al., 2019). RNF8 activated K63 ubiquitination of Twist, which induced its translocation to the nucleus for subsequent EMT and CSC functions, thereby conferring doxorubicin resistance (Lee et al., 2016). SMO stabilizes and activates TRAF6, suggesting that the SMO/TRAF6 axis can contribute to doxorubicin resistance in lymphoma (Qu et al., 2018).
Dysregulated cholesterol metabolism in cancer cells may lead to drug resistance. Lower expression of the E3 Trc8 produced a decreased ubiquitination rate of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCoAR), increased cholesterol synthesis, and increased cholesterol content in multidrug-resistant cells (Gelsomino et al., 2013). Overexpression of the E3 ubiquitin-protein ligase ZNRF2 improved cell survival in the presence of doxorubicin (Xiao et al., 2017). TRIM25 regulated p53 expression in NSCLC tissues and cell lines. Using TRIM25 RNAi increased the doxorubicin sensitivity of lung cancer cell lines (Qin et al., 2016). CUL2 knockdown enhanced cell sensitivity to doxorubicin treatment by regulating MAF1-mediated actin stress fiber integrity and apoptosis (Wang et al., 2019). MDM2, an E3 targeting p53 for degradation, can influence PC and BC cell sensitivity to doxorubicin (Lang et al., 2017; Cheteh et al., 2020). FKBP12 attenuated the cell toxicity of doxorubicin by binding to and degrading MDM2, disrupting the MDM2/MDM4 interaction, and inducing MDM2 self-ubiquitination (Liu et al., 2017). Cbl-b was found to be poorly expressed in multidrug-resistant GC and GC cells. In addition, Cbl was also found to induce cell resistance to adriamycin (Xu et al., 2017; X CHe et al., 2017; Zhang et al., 2015).
Endocrine Drugs
Endocrine therapy is an optional treatment for patients with hormone sensitivity, especially in PC and BC (Heinlein and Chang, 2004; Waks and Winer, 2019). Androgenic drugs such as abiraterone and enzalutamide can control the progression of PC.
Persistent androgen receptor (AR) activation leads to the loss of efficacy of anti-AR drugs in advanced PC. Reversal of this aberrant activation could be an ideal method for overcoming drug resistance. STUB1 disassociates AR/AR-V7 from HSP70, leading to AR/AR-V7 ubiquitination and degradation, which confers enzalutamide and abiraterone resistance (Liu et al., 2018). Inhibition of protein degradation by blocking Cullin-RING E3 complexes can interfere with the AR–ERG interaction, which is related to survival in PC (Rulina et al., 2016). AMFR can mediate the loss of 11b-hydroxysteroid dehydrogenase-2 (11b-HSD2), which inactivates cortisol, sustaining tumor cortisol concentrations to stimulate enzalutamide resistance. Reinstatement of 11b-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors (Li et al., 2017).
Tamoxifen, a blocker of estrogen in breast cells, remains a cornerstone in the treatment of BC patients with estrogen receptor-positive tumors (Jordan, 2003). The RING finger protein TRIM2 is highly expressed in tamoxifen-resistant MCF-7 cells. TRIM2 was overexpressed in tamoxifen-resistant BC cells, which led to a reduction in Bim (Yin et al., 2017). The E3 HRD1 was downregulated in tamoxifen-resistant BC cells, and its knockdown significantly increased the survival of MCF7 cells treated with tamoxifen (Wang et al., 2017). The E3 RBCK1 regulated FKBPL stability at the posttranslational level via ubiquitination, and its downregulation increased sensitivity to tamoxifen treatment (Donley et al., 2014). The FBXW2-mediated downregulation of Sox2, a transcription factor conferring drug resistance, suppressed stem cell properties and overcame BC cell resistance to tamoxifen (Yin et al., 2019). The ubiquitin ligase c-Cbl was upregulated during tamoxifen-induced apoptosis of MCF-7 cells. Overexpression of c-Cbl significantly downregulated c-Src protein levels and tamoxifen-induced AKT activity (Yan et al., 2011). In addition, SIAH2 expression is significantly correlated with ER positivity in BC. SIAH2 sensitizes cells to tamoxifen through regulation of ER-a expression (Interiano et al., 2014).
Targeted Drugs
The fusion of BCR (located on chromosome 22q11.2) and ABL1 (located on chromosome 9q34) leads to chronic myeloid leukemia (CML) (Baccarani et al., 2019). Imatinib is a tyrosine kinase inhibitor that can selectively inhibit BCR/ABL kinase activity and function as an effective therapy for CML. Smith PG et al. found that TGFβ played a key role in imatinib resistance by directly affecting c-Cbl-dependent Lyn ubiquitination and turnover, which resulted in bursts of Lyn kinase activity (Smith et al., 2012). TRAF6, an E3, facilitates the K63 ubiquitination of ULK1, resulting in reversal of imatinib resistance in CML cells (Han et al., 2019). LZTR1 acts as the regulator of RAS ubiquitination and MAPK pathway activation. Johannels W et al. reported that loss of LZTR1 expression could induce resistance to imatinib and rebastinib in CML cell lines (Bigenzahn et al., 2018).
Bortezomib is an effective proteasome inhibitor for cancer treatment that reversibly and selectively inhibits the 20S proteasome (Scott et al., 2016). Using an RNA microarray, researchers found that genes related to ubiquitination were differentially regulated in a bortezomib-resistant cell line (Park et al., 2014). NEDD4-1 ubiquitinates Akt and targets pAkt-Ser473 for proteasomal degradation. Low NEDD4-1 expression has been linked to poor prognosis in patients with multiple myeloma (MM), and NEDD4-1 knockdown results in bortezomib resistance in vitro and in vivo (Huang et al., 2020). Additionally, BAP1 depletion resulted in decreased gallbladder carcinoma (GBC) sensitivity to bortezomib (Hirosawa et al., 2018). Shen Y et al. demonstrated that silencing DTX3L improved the sensitivity to bortezomib in MM cell lines and increased the expression of apoptosis biomarkers (Shen et al., 2017). Malek E et al. observed increased CUL1 and SKP2 mRNA levels in patient CD138 + cells. Skp2 binds to Cullin-1 and Commd1 and synergistically enhances bortezomib-induced apoptosis (Malek et al., 2017).
Targeting HER2 with an inhibitor can be a treatment strategy for HER-2-positive BC or GC. c-Cbl and CHIP can interact and ubiquitinate HER2, which can be an effective strategy for combatting lapatinib resistance in HER2-positive cancer (Nunes et al., 2016; Huang et al., 2020). In addition, Skp2 silencing sensitized Her2-overexpressing tumors to trastuzumab treatment (Chan et al., 2012). MDM2 inhibition overcame lapatinib resistance in cells with either wild-type or mutant p53 and xenograft models, suggesting the potential of therapy directed against MDM2 for overcoming lapatinib resistance (Kurokawa et al., 2013). In GC, miR-223, which can regulate FBXW7, decreased GC cell sensitivity to trastuzumab (Eto et al., 2015). Jagged-1-mediated activation of Notch-1 can lead to trastuzumab resistance. The E3 Mindbomb-1 was required for Jagged-1 ubiquitination and subsequent Notch activation, which led to resistance to trastuzumab (Pandya et al., 2016).
Targeting aberrant EGFR expression in cancer cells is a promising treatment strategy for NSCLC. Activation of the Hippo-YAP pathway was correlated with EGFR inhibitor treatment (Kim and Myung, 2018). Wang H et al. identified tankyrase and its associated E3 RNF146 as positive YAP activity regulators by CRISPR screening. Tankyrase inhibition by RNF146 enhanced the growth inhibitory activity of EGFR inhibitors in NSCLC by inhibiting YAP signaling (Wang et al., 2016). FBXW7 regulated quiescence by targeting the c-MYC protein for ubiquitination. High levels of FBXW7 and low levels of c-MYC were observed in gefitinib-resistant cells with EGFR exon 19 deletion, suggesting that FBXW7 plays a pivotal role in the maintenance of gefitinib resistance in EGFR mutation-positive NSCLC (Hidayat et al., 2019). Cetuximab is a monoclonal antibody with a molecular target of EGFR. Specific silencing of Cbl-b expression increased the expression of EGFR and decreased the sensitivity of GC cells to cetuximab (Yu et al., 2016).
Regorafenib and sorafenib are multikinase inhibitors of RAS/RAF/MEK/ERK signaling that function to prevent tumors. CRC cells containing FBW7-inactivating mutations, including missense mutations in three arginine residues (R465, R479, and R505), were found to be insensitive to regorafenib and sorafenib (Tong et al., 2017). Nanog is a master transcriptional regulator of stemness in CSCs. The E3 FBXW8 ubiquitinates Nanog and suppresses Nanog expression, resulting in stemness enhancement and sorafenib resistance (Cao et al., 2019).
JQ1 and I-BET, two selective inhibitors of the bromodomain and extraterminal (BET) family, have shown promising early clinical trial outcomes. Xiangpeng Dai et al. found that cullin-3SPOP was responsible for promoting BET protein degradation. PC cell lines derived from individuals harboring SPOP mutations had increased resistance to BET inhibitor-induced cell growth arrest and apoptosis (Dai et al., 2017). Moreover, specific SPOP mutations could impair BET degradation (Janouskova et al., 2017).
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provide rapid disease control in patients with BRAF-mutant metastatic melanoma (Kuske et al., 2018). BRAFi/MEKi resistance triggers proteasomal degradation of AMPK-α1 and consequently drives autophagy and metabolic reprogramming in melanoma cells. Li YY et al. discovered that RING finger 44 (RNF44) could earmark AMPK-α1 for ubiquitination-mediated degradation in BRAFi-resistant melanoma cells (Li et al., 2017). PARP inhibitors (PARPi) are used clinically to treat BRCA-mutated breast tumors. FBXO5 assembles the active SCF ubiquitin ligase complex constitutively targeting RAD51 for degradation. This mechanism controls BC biology and sensitivity to PARPi (Marzio et al., 2019). The E3s involved in the response to non-platinum anticancer drugs are listed in Table 1.
TABLE 1
| Classification | Drug | Cancer | E3 ligase | Mechanism | Role | Ref |
|---|---|---|---|---|---|---|
| Plants | Taxol | NSCLC | FBXW7 | FBXW7/MCL1/PLK1 | Sensitive | Gasca et al. (2016) |
| GC | FBXW7 | MiR-363/FBXW7 | Sensitive | Su et al. (2011) | ||
| BC/OC/NPC | FBXW11 | FBXW11/E1A/FOXO3 | Resistance | Yang et al. (2016) | ||
| NSCLC | Pirh2 | Pirh2/p53 | Resistance | Bian et al. (2020) | ||
| BC | Parkin | Microtubule assembly/stabilization | Sensitive | Kim et al. (2015) | ||
| Melanoma | SIAH2 | miR-335/SIAH2/HDAC3 | Resistance | Lukenbill and Kalaycio (2013) | ||
| Docetaxel | PC | EDD | Wnt/β-Catenin | Resistance | Becker et al. (2008) | |
| SPOP | SPOP/Caprin | Sensitive | Wang et al. (2009) | |||
| Camptothecin | CRC | HAUSP | p53/Mdm2 | Sensitive | Shi et al. (2019) | |
| Anti-metabolite | Fludarabine | HCC | COP1 | COP1/p53-brn-3a/Bcl-2 | Sensitive | Longley et al. (2003) |
| 5-Fluorouracil | BC | Skp2 | Skp2/p27Kip1 | Resistance | Kadera et al. (2015) | |
| PDACs | CBL | CBL/EGFR | Sensitive | Liang et al. (2019) | ||
| CRC | TRIM47 | TRIM47/SMAD4 | Resistance | Fang et al. (2015) | ||
| FBXW7 | FBXW7/CRY2 | Sensitive | Kalluri, (2016) | |||
| RBCK1 | Microenvironment/CAF | Resistance | Mini et al. (2006) | |||
| Gemcitabine | PCC | FBXW7 | FBW7/ENT1 | Sensitive | Zhang et al. (2015) | |
| SMURF2 | miR-15b/SMURF2/EMT | Sensitive | Yu et al. (2018) | |||
| TRIM31 | TRIM31/TRAF2/NF-κB | Sensitive | Hung et al. (2015) | |||
| NSCLC | Cul4A | Cul4A/TGFβ1 | Resistance | Asselin and Rizzari (2015) | ||
| Asparaginase | Leukemias | FBXW7 | Wnt pathway | Sensitive | Bhatt et al. (2017) | |
| Alkylating | Temozolomide | GBM | HERC3 | HERC3/SMAD7/TGFβ1 | Resistance | Ko et al. (2018) |
| GBM | MDM2 | MDM2/NCL/HDAC | Resistance | Kamran et al. (2017) | ||
| Antibiotics | Doxorubicin | GC | FBXL7 | AURKA/FBXL7/Survivin | Sensitive | Kamran et al. (2017) |
| CRC | FBXO15 | FBXO15/P-gp/mdr | Sensitive | Long et al. (2019) | ||
| HCC | CUL2 | CUL2/MAF-1 | Resistance | Cheteh et al. (2020) | ||
| HCC | FBXW7 | FBXW7/HSF1/MDR1 | Sensitive | Lin and Yamazaki, (2003) | ||
| HCC | SIAH1 | SIAH1/Zeb1/EMT | Resistance | Lee et al. (2016) | ||
| Lymphoma | TRAF6 | SMO/TRAF6 | Resistance | Gelsomino et al., 2013) | ||
| Colon cancer | Trc8 | Trc8/HMGCoAR/MDR | Resistance | Xiao et al. (2017) | ||
| Osteosarcoma | ZNRF2 | miR-100/ZNRF2 | Resistance | Qin et al. (2016) | ||
| NSCLC | TRIM25 | TRIM25/p53 | Resistance | Wang et al. (2019) | ||
| PC/BC | MDM2 | FKBP12/MDM2/p53 | Resistance | Xu et al. (2017) | ||
| Adriamycin | BC/GC | Cbl-b | Cbl-b/EGFR/Akt-miR-200c-ZEB1 axis | Resistance | X CH et al. (2017); Zhang et al. (2015); Waks and Winer (2019) | |
| Endocrine | Enzalutamide/abiraterone | PC | STUB1 | STUB1/ar/ar-v7/HSP70 | Resistance | Rulina et al. (2016) |
| PC | Cullin-RING | AR–ERG/Wnt/β-catenin pathway/NF-κB pathway | Resistance | Li et al. (2017) | ||
| Enzalutamide | PC | AMFR | 11b-HSD2/cortisol | Resistance | Jordan (2003) | |
| Tamoxifen | BC | TRIM2 | Bim/cleaved PARP/caspase 3 | Resistance | Wang et al. (2017) | |
| HRD1 | S100A8/HRD1 | Sensitive | Donley et al. (2014) | |||
| RBCK1 | RBCK1/FKBPL/ERa | Resistance | Yin et al. (2019) | |||
| FBXW2 | FBXW2/Sox2 | Sensitive | Yan et al. (2011) | |||
| c-Cbl | c-Cbl/c-src/AKT | Resistance | Interiano et al. (2014) | |||
| SIAH2 | SIAH2/ER-a | Sensitive | Baccarani et al. (2019) | |||
| Targeted drugs | Imatinib | CML | c-Cbl | TGFβ/c-cbl/Lyn kinase activity | Resistance | Han et al. (2019) |
| TRAF6 | TRAF6/ULK1 | Sensitive | Bigenzahn et al. (2018) | |||
| Imatinib/rebastinib | CML | LZTR1 | LZTR1/RAS/MAPK pathway | Sensitive | Scott et al. (2016) | |
| Bortezomib | MM | NEDD4-1 | NEDD4-1/AKT | Sensitive | Hirosawa et al. (2018); Hirosawa et al. (2018) | |
| DTX3L | Cleaved PARP/caspase 3 | Resistance | Malek et al. (2017) | |||
| Skp2 | Cullin-1/Commd1/caspase 3 | Resistance | Huang et al. (2020) | |||
| Lapatinib | BC/GC | c-Cbl/CHIP | HER2 degration | Sensitive | Nunes et al. (2016); Chan et al. (2012) | |
| Trastuzumab | BC | Skp2 | AKT/Glut1/glucose uptake/glycolysis | Resistance | Kurokawa et al. (2013) | |
| GC | FBXW7 | miR-223/FBXW7 | Resistance | Pandya et al. (2016) | ||
| BC | Mindbomb-1 | Mindbomb-1/Jagged-1/Notch activation | Resistance | Kim and Myung (2018) | ||
| Lapatinib | BC | MDM2 | P53 | Resistance | Eto et al. (2015) | |
| Erlotinib | NSCLC | RNF146 | RNF146/Hippo-YAP pathway | Resistance | Hidayat et al. (2019) | |
| Gefitinib | NSCLC | FBXW7 | FBXW7/c-MYC | Resistance | Yu et al. (2016) | |
| Cetuximab | GC | Cbl-b | Cbl-b/EGFR | Resistance | Tong et al. (2017) | |
| Sorafenib | HCC | FBXW8 | Nanog/CSCs | Resistance | Dai et al. (2017) | |
| JQ1/I-BET | PC | Cullin-3SPOP | Cullin-3SPOP/BET | Resistance | Janouskova et al. (2017); Kuske et al. (2018) | |
| BRAFi/MEKi | Melanoma | RNF44 | AMPK-α1/autophagy/metabolic | Resistance | Marzio et al. (2019) | |
| PARP inhibitors | BC | FBXO5 | SCF complex/RAD51 | Sensitive | Zhao et al. (2020) |
Representative E3 ligase involved in non-platinum anti-cancer drug resistance.
Discussion
“Druggability” of E3s
The purpose of studying the mechanisms of resistance is to identify strategies to combat resistance. E3s control tumor drug resistance by specifically binding to drug resistance-related genes and controlling their expression. Therefore, targeting E3 ligases can serve as a potential and effective strategy for combatting drug resistance. In the current environment, studying the resistance mechanisms of all existing E3s is challenging and impractical. However, some E3s have shown their ability to combat resistance. Several kinds of E3s have been deemed “druggable”. First, E3s that target key pathway molecules, like Cbl, which targets EGFR, and NEDD4, which targets AKT, have potential (Zhao et al., 2020). Second, E3s targeting important oncogenes have also been proposed to be druggable. E3s like MDM2, which targets p53, FBXW2, which targets Sox2, and FBXW7, which targets MYC, have shown value in combating drug resistance.
Targeting E3s to Combat Drug Resistance
Ongoing research mainly focuses on potential drugs that can be used in therapeutic applications targeting E3s. Such drugs must directly target the E3s to exert their effect; this requirement fits with several different tools, such as siRNAs, agonists, small molecule compounds that affect the binding of E3s to target proteins, and PROteolysis TArgeting Chimera (PROTAC) technology. Strategies targeting E3s include using small molecules or PROTACs that degrade E3s or interfere with the interaction between E3s and their substrates.
Small Molecules Targeting E3s
Small molecules can target different E3s by directly binding with them and inhibiting their enzymatic activity. As mentioned above, MDM2 is a selective E3 that binds to P53. Agents that inhibit MDM2 include Nutlin-3a, RG7112, NVP-CGM097, AMG-232 and MI319. The combination of traditional anticancer drugs with novel agents was better for drug efficacy than monotherapy (Azmi et al., 1990; Kojima et al., 2006; Vu et al., 2013; Reuther et al., 2018) (Figure 3). These data suggest that targeting relevant E3s with small molecules to overcome drug resistance could be effective. Agonists have also been shown to be effective in controlling drug resistance. The PPARγ agonist pioglitazone inhibited EGFR/MDM2 signaling-mediated PPARγ degradation and increased cancer cell sensitivity to chemotherapy drugs (Shi et al., 2016).
FIGURE 3
Interfering With the Interaction Between E3s and Their Substrates
Another strategy for combating drug resistance is interfering with the interaction between E3s and their target substrates. Using chemical library screens, E Malek et al. identified a novel compound, DT204, that reduced Skp2 binding to Cullin-1 and Commd1 and synergistically enhanced bortezomib-induced apoptosis (Malek et al., 2017). Small molecules have also been used to interfere with the interaction between EGFR and its E3. The downregulation of EGFR ubiquitination inhibits the internalization of EGFR, which is an essential mechanism of EGFR activation and drug resistance (Yu et al., 2020).
Traditional Drugs Targeting E3s
Traditional drugs also facilitate the ubiquitination of E3s. Vitamin K3, an inhibitor of Siah2, promoted sensitivity of leukemia cells to imatinib (Huang et al., 2018). ATA is a molecular compound derived from Tanshinone IIA through chemical modification (Tian et al., 2010). A mechanistic study revealed that ATA promoted HER2 degradation by increasing c-Cbl and CHIP-mediated HER2 ubiquitination (Huang et al., 2020). Oridonin is a natural compound inducing oxidative stress that enhances CHIP targeting of BCR-ABL for ubiquitin-proteasome degradation, resulting in the enhancement of cancer cell death (Huang et al., 2017). Ginsenoside RD is another natural compound that increases the ubiquitination of multidrug resistance 1 (MDR1). Ginsenoside Rd treatment can reverse doxorubicin resistance in MCF-7/ADR cells (Pokharel et al., 2010).
PROTACs That Degrade E3s
PROTAC technology utilizes the ubiquitin‐protease system to target a specific protein for ubiquitination and degradation (Sakamoto et al., 2001). PROTAC technology targets proteins, including transcription factors, skeletal proteins, enzymes, and regulatory factors (Zhang et al., 2018). Targeting oncogene family proteins using PROTACs to overcome drug resistance has recently become a popular area of research.
PROTACs directly targeting oncogenes are a tool for overcoming drug resistance. Ibrutinib resistance can occur due to a cysteine to serine mutation (C481S) in the site normally covalently bound by ibrutinib. Alexandru D. Buhimschi et al. introduced MT-802, which is a PROTAC that induces ubiquitination-dependent degradation of wild-type and C481S-mutant BTK from PROTAC, which could be a novel tool for overcoming ibrutinib resistance (Buhimschi et al., 2018). CP5V (apcin-A-PEG5-VHL ligand 1), as an efficient Cdc20 PROTAC, can mediate degradation of the oncogene Cdc20 through the ubiquitous pathway and overcome resistance to taxane chemotherapy in BC by inhibiting mitotic slippage (Chi et al., 2019). The SH2-U-box targets both native and T315I-mutant BCR-ABL for ubiquitination and degradation and thus may serve as a tool for treating both imatinib-sensitive and imatinib-resistant CML (Ru et al., 2016).
Limitations of Targeting E3s to Combat Drug Resistance
In summary, E3s can play a role in tumor resistance by binding oncogenes or pathway proteins. Degrading E3s via different strategies or affecting their function can be used as strategies for anticancer treatment. However, E3s have some shortcomings in treating drug resistance. The first is the diversity of E3s, which prevents a complete understanding of all of the E3 functions and their corresponding target genes. The second is that E3s can bind to multiple different oncogenes. For example, TRIM family proteins perform different functions by binding to different oncogenes. The same E3 not only combines with one oncogene or tumor suppressor gene but also can interact with multiple oncogenes or tumor suppressor genes at the same time. Directly targeting E3s in anti-drug resistance research may lead to failure.
Conclusion
Drug resistance has been a prominent factor negatively affecting clinical treatment. Various E3s target oncogenes or tumor suppressors, affecting the sensitivity of tumor cells to different drug treatments. Strategies that target E3s to combat drug resistance include interfering with E3 activators, degrading E3s and affecting the interaction between E3s and their substrates. Some famous E3s, like MDM2, FBWX7, and SKP2, have been well studied and shown to have value for treating drug resistance. Research on E3s has led to the discovery of possible therapeutic methods to overcome the challenging clinical situation imposed by drug resistance.
Statements
Author contributions
YL was contributed to the acquisition, analysis, and interpretation of data. CD and CZ was contributed to the conception and design; revising the article for important intellectual content; final approval of the version to be published.
Funding
This work was supported by grants from National Natural Science Foundation of China (81372515), National Natural Science Youth Foundation of China (81602027,81702928), Natural Science Foundation General Program of Hunan Province (2018JJ3821), Natural Science Foundation Youth Program of Hunan Province (806288981033), Project of Scientific Research Plan of Hunan Provincial Health Commission (C2019185) and the Youth Foundation of Xiangya Hospital Central South University (2015Q01).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbediniM. R.MullerE. J.BergeronR.GrayD. A.TsangB. K. (2010). Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene29 (1), 11–25. 10.1038/onc.2009.300
2
AbediniM. R.MullerE. J.BrunJ.BergeronR.GrayD. A.TsangB. K. (2008). Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res.68 (12), 4511–4517. 10.1158/0008-5472.Can-08-0673
3
AsselinB.RizzariC. (2015). Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk. Lymphoma56 (8), 2273–2280. 10.3109/10428194.2014.1003056
4
AzmiA. S.AboukameelA.BanerjeeS.WangZ.MohammadM.WuJ.et al (1990). MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer, 46 (6). Oxford, England, 1122–1131. 10.1016/j.ejca.2010.01.015
5
BaccaraniM.RostiG.SoveriniS. (2019). Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia33 (10), 2358–2364. 10.1038/s41375-019-0562-1
6
BeckerK.MarchenkoN. D.PalaciosG.MollU. M. (2008). A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle (Georgetown, Tex)7 (9), 1205–1213. 10.4161/cc.7.9.5756
7
BennettE. J.HarperJ. W. (2008). DNA damage: ubiquitin marks the spot. Nat. Struct. Mol. Biol.15 (1), 20–22. 10.1038/nsmb0108-20
8
BernabeuE.CagelM.LagomarsinoE.MorettonM.ChiappettaD. A. (2017). Paclitaxel: what has been done and the challenges remain ahead. Int. J. pharmaceutics526 (1-2), 474–495. 10.1016/j.ijpharm.2017.05.016
9
BerndsenC. E.WolbergerC. (2014). New insights into ubiquitin E3 ligase mechanism. Nat. Struct. Mol. Biol.21 (4), 301–307. 10.1038/nsmb.2780
10
BhattL.SebastianB.JoshiV. (2017). Mangiferin protects rat myocardial tissue against cyclophosphamide induced cardiotoxicity. J. Ayurveda Integr. Med.8 (2), 62–67. 10.1016/j.jaim.2017.04.006
11
BianP.DouZ.JiaZ.LiW.PanD. (2020). Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. Life Sci.254, 116816. 10.1016/j.lfs.2019.116816
12
BigenzahnJ. W.ColluG. M.KartnigF.PieraksM.VladimerG. I.HeinzL. X.et al (2018). LZTR1 is a regulator of RAS ubiquitination and signaling. Science (New York, NY)362 (6419), 1171–1177. 10.1126/science.aap8210
13
BradleyA.ZhengH.ZiebarthA.SakatiW.Branham-O'ConnorM.BlumerJ. B.et al (2014). EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis35 (5), 1100–1109. 10.1093/carcin/bgt489
14
BuetowL.HuangD. T. (2016). Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cel. Biol.17 (10), 626–642. 10.1038/nrm.2016.91
15
BuhimschiA. D.ArmstrongH. A.ToureM.Jaime-FigueroaS.ChenT. L. (2018). Targeting the C481S ibrutinib‐resistance mutation in bruton's tyrosine kinase using PROTAC‐mediated degradation. Biochemistry57 (26), 3564–3575.
16
CaoJ.ZhaoM.LiuJ.ZhangX.PeiY.WangJ.et al (2019). RACK1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing Nanog. Theranostics9 (3), 811–828. 10.7150/thno.29271
17
CappadociaL.LimaC. D. (2018). Ubiquitin-like protein conjugation: structures, chemistry, and mechanism. Chem. Rev.118 (3), 889–918. 10.1021/acs.chemrev.6b00737
18
ChanC. H.LiC. F.YangW. L.GaoY.LeeS. W.FengZ.et al (2012). The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell149 (5), 1098–1111. 10.1016/j.cell.2012.02.065
19
ChenZ. J.SunL. J. (2009). Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cel.33 (3), 275–286. 10.1016/j.molcel.2009.01.014
20
ChetehE. H.SarneV.CederS.BianchiJ.AugstenM.RundqvistH.et al (2020). Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov6, 42. 10.1038/s41420-020-0272-5
21
ChiJ. J.LiH.ZhouZ.Izquierdo-FerrerJ.XueY.WaveletC. M.et al (2019). A novel strategy to block mitotic progression for targeted therapy. EBioMedicine49, 40–54. 10.1016/j.ebiom.2019.10.013
22
CiechanoverA. (2015). The unravelling of the ubiquitin system. Nat. Rev. Mol. Cel. Biol.16 (5), 322–324. 10.1038/nrm3982
23
ColalucaI. N.TosoniD.NuciforoP.Senic-MatugliaF.GalimbertiV.VialeG.et al (2008). NUMB controls p53 tumour suppressor activity. Nature451 (7174), 76–80. 10.1038/nature06412
24
CuiX.LinZ.ChenY.MaoX.NiW.LiuJ.et al (2016). Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma. Mol. Cell. Biochem.421 (1-2), 127–137. 10.1007/s11010-016-2793-z
25
DaiX.GanW.LiX.WangS.ZhangW.HuangL.et al (2017). Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med.23 (9), 1063–1071. 10.1038/nm.4378
26
DaksA.PetukhovA.FedorovaO.ShuvalovO.MerkulovV.VasilevaE.et al (2016). E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells. Genes & cancer7 (11-12), 383–393. 10.18632/genesandcancer.123
27
DavidovichS.Ben-IzhakO.ShapiraM.FutermanB.HershkoD. D. (2008). Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast cancer researchBCR10 (4), R63. 10.1186/bcr2122
28
DonleyC.McClellandK.McKeenH. D.NelsonL.YakkundiA.JitheshP. V.et al (2014). Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. Oncogene33 (26), 3441–3450. 10.1038/onc.2013.306
29
EnglingerB.MairM.MiklosW.PirkerC.MohrT.van SchoonhovenS.et al (2017). Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. Br. J. Cancer116 (4), 489–500. 10.1038/bjc.2016.449
30
EtoK.IwatsukiM.WatanabeM.IshimotoT.IdaS.ImamuraY.et al (2015). The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int. J. Cancer J. Int. du Cancer136 (7), 1537–1545. 10.1002/ijc.29168
31
FangL.YangZ.ZhouJ.TungJ. Y.HsiaoC. D.WangL.et al (2015). Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Mol. Cancer Ther.14 (6), 1476–1487. 10.1158/1535-7163.Mct-15-0030
32
FengS.YangG.YangH.LiangZ.ZhangR.FanY.et al (2017). NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells. Cel Cycle (Georgetown, Tex)16 (9), 869–878. 10.1080/15384101.2017.1308617
33
FuC.ShiX.GongY.WanY.SunZ.ShiH.et al (2018). Constitutively photomorphogenic 1 reduces the sensitivity of chronic lymphocytic leukemia cells to fludarabine through promotion of ubiquitin-mediated P53 degradation. Cell Physiol. Biochem. : Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.50 (6), 2314–2328. 10.1159/000495092
34
GascaJ.FloresM. L.GiráldezS.Ruiz-BorregoM.TortoleroM.RomeroF.et al (2016). Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. Oncotarget7 (33), 52751–52765. 10.18632/oncotarget.10481
35
GelsominoG.CorsettoP. A.CampiaI.MontorfanoG.KopeckaJ.CastellaB.et al (2013). Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol. Cancer12, 137. 10.1186/1476-4598-12-137
36
GlickmanM. S.SawyersC. L. (2012). Converting cancer therapies into cures: lessons from infectious diseases. Cell148 (6), 1089–1098. 10.1016/j.cell.2012.02.015
37
GongJ.ZhouY.LiuD.HuoJ. (2018). F-box proteins involved in cancer-associated drug resistance. Oncol. Lett.15 (6), 8891–8900. 10.3892/ol.2018.8500
38
GuodongX.YuanL.MengW.XiangL.SidaQ.XinS.et al (2018). FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation. Xi'an, China. Cell. Prolif.51 (5). e12473. 10.1111/cpr.12473
39
HanS. H.KormS.HanY. G.ChoiS. Y.KimS. H.ChungH. J.et al (2019). GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia. Autophagy, 15. 2076-2090. 10.1080/15548627.2019.1596492
40
HatakeyamaS. (2017). TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochemical Sciences42 (4), 297–311. 10.1016/j.tibs.2017.01.002
41
HeR.LiuH. (2020). TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2. Gene747, 144553. 10.1016/j.gene.2020.144553
42
HeinleinC. A.ChangC. (2004). Androgen receptor in prostate cancer. Endocr. Rev.25 (2), 276–308. 10.1210/er.2002-0032
43
HidayatM.MitsuishiY.TakahashiF.TajimaK.YaeT.MiyaharaK.et al (2019). Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer. Bosn J. Basic Med. Sci.19 (4), 355–367. 10.17305/bjbms.2019.4227
44
HinzeL.PfirrmannM.KarimS.DegarJ.McGuckinC.VinjamurD.et al (2019). Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer cell35 (4), 664–676. 10.1016/j.ccell.2019.03.004.e7
45
HirosawaT.IshidaM.IshiiK.KaneharaK.KudoK.OhnumaS.et al (2018). Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer. PloS one13 (11), e0206643. 10.1371/journal.pone.0206643
46
HuQ.QinY.ZhangB.LiangC.JiS.ShiS.et al (2017). FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncol. Rep.38 (4), 2069–2077. 10.3892/or.2017.5856
47
HuX.MengY.XuL.QiuL.WeiM.SuD.et al (2019). Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3. Cel Death Dis.10 (2), 104. 10.1038/s41419-018-1200-y
48
HuangB.YipW. K.WeiN.LuoK. Q. (2020). Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells. Cancer Lett.490, 1–11. 10.1016/j.canlet.2020.06.010
49
HuangH.WengH.DongB.ZhaoP.ZhouH.QuL. (2017). Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia. Scientific Rep.7, 41525. 10.1038/srep41525
50
HuangJ.LuZ.XiaoY.HeB.PanC.ZhouX.et al (2018). Inhibition of Siah2 ubiquitin ligase by vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment. Med. Sci. monitor : Int. Med. J. Exp. Clin. Res.24, 727–735. 10.12659/msm.908553
51
HuangX.GuH.ZhangE.ChenQ.CaoW.YanH.et al (2020). The NEDD4-1 E3 ubiquitin ligase: a potential molecular target for bortezomib sensitivity in multiple myeloma. Int. J. Cancer J. Int. du Cancer146 (7), 1963–1978. 10.1002/ijc.32615
52
HungM. S.ChenI. C.YouL.JablonsD. M.LiY. C.MaoJ. H.et al (2015). Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncol. Rep.34 (6), 3187–3195. 10.3892/or.2015.4324
53
IkedaF.DikicI. (2008). Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: beyond the Usual Suspects' review series. EMBO Rep.9 (6), 536–542. 10.1038/embor.2008.93
54
InterianoR. B.YangJ.HarrisA. L.DavidoffA. M. (2014). Seven in Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. J. Surg. Res.190 (1), 203–209. 10.1016/j.jss.2014.02.018
55
IshiiT.MatsuseT.MasudaM.TeramotoS. (2004). The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells. Exp. Lung Res.30 (8), 687–703. 10.1080/01902140490517818
56
JanouskovaH.El TekleG.BelliniE.UdeshiN. D.RinaldiA.UlbrichtA.et al (2017). Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat. Med.23 (9), 1046–1054. 10.1038/nm.4372
57
JeonY. K.KimC. K.KohJ.ChungD. H.HaG. H. (2016). Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination. Oncotarget7 (27), 41811–41824. 10.18632/oncotarget.9619
58
JordanV. C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov.2 (3), 205–213. 10.1038/nrd1031
59
KaderaB. E.TosteP. A.WuN.LiL.NguyenA. H.DawsonD. W.et al (2015). Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin. Cancer Res. : official J. Am. Assoc. Cancer Res.21 (1), 157–165. 10.1158/1078-0432.Ccr-14-0610
60
KalluriR. (2016). The biology and function of fibroblasts in cancer. Nat. Rev. Cancer16 (9), 582–598. 10.1038/nrc.2016.73
61
KamranM.LongZ. J.XuD.LvS. S.LiuB.WangC. L.et al (2017). Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis6 (2), e298. 10.1038/oncsis.2016.80
62
KatayamaK.FujiwaraC.NoguchiK.SugimotoY. (2016). RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1. Scientific Rep.6, 36134. 10.1038/srep36134
63
KatayamaK.NoguchiK.SugimotoY. (2013). FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells. Cancer Sci.104 (6), 694–702. 10.1111/cas.12145
64
KimH. B.MyungS. J. (2018). Clinical implications of the Hippo-YAP pathway in multiple cancer contexts. BMB Rep.51 (3), 119–125. 10.5483/bmbrep.2018.51.3.018
65
KimJ.XuS.XiongL.YuL.FuX.XuY. (2017). SALL4 promotes glycolysis and chromatin remodeling via modulating HP1α-Glut1 pathway. Oncogene36 (46), 6472–6479. 10.1038/onc.2017.265
66
KimY.KimH.ParkD.JeoungD. (2015). miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3. Mol. Cell38 (6), 562–572. 10.14348/molcells.2015.0051
67
KoC. Y.LinC. H.ChuangJ. Y.ChangW. C.HsuT. I. (2018). MDM2 degrades deacetylated nucleolin through ubiquitination to promote glioma stem-like cell enrichment for chemotherapeutic resistance. Mol. Neurobiol.55 (4), 3211–3223. 10.1007/s12035-017-0569-4
68
KojimaK.KonoplevaM.McQueenT.O'BrienS.PlunkettW.AndreeffM. (2006). Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood108 (3), 993–1000. 10.1182/blood-2005-12-5148
69
KurokawaM.KimJ.GeradtsJ.MatsuuraK.LiuL.RanX.et al (2013). A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci. signaling6 (274), ra32. 10.1126/scisignal.2003741
70
KuskeM.WestphalD.WehnerR.SchmitzM.BeissertS.PraetoriusC.et al (2018). Immunomodulatory effects of BRAF and MEK inhibitors: implications for Melanoma therapy. Pharmacol. Res.136, 151–159. 10.1016/j.phrs.2018.08.019
71
LajousH.LelièvreB.VauléonE.LecomteP.GarcionE. (2019). Rethinking alkylating(-like) agents for solid tumor management. Trends Pharmacological Sciences40 (5), 342–357. 10.1016/j.tips.2019.03.003
72
LangV.AilletF.XolalpaW.SernaS.CeccatoL.Lopez-ReyesR. G.et al (2017). Analysis of defective protein ubiquitylation associated to adriamycin resistant cells. Cel Cycle (Georgetown, Tex)16 (24), 2337–2344. 10.1080/15384101.2017.1387694
73
LeeH. J.LiC. F.RuanD.PowersS.ThompsonP. A.FrohmanM. A.et al (2016). The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through twist activation. Mol. Cel.63 (6), 1021–1033. 10.1016/j.molcel.2016.08.009
74
LeeJ.AnS.JungJ. H.KimK.KimJ. Y.AnI. S.et al (2019). MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation. Int. J. Oncol.54 (5), 1833–1842. 10.3892/ijo.2019.4730
75
LiG.CiW.KarmakarS.ChenK.DharR.FanZ.et al (2014). SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer cell25 (4), 455–468. 10.1016/j.ccr.2014.02.007
76
LiH.LiJ.ChenL.QiS.YuS.WengZ.et al (2019). HERC3-Mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma. Clin. Cancer Res. : official J. Am. Assoc. Cancer Res.25 (12), 3602–3616. 10.1158/1078-0432.Ccr-18-3791
77
LiJ.AlyamaniM.ZhangA.ChangK. H.BerkM.LiZ.et al (2017). Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.eLife6. e20183. 10.7554/eLife.20183
78
LiN.LorenziF.KalakoutiE.NormatovaM.Babaei-JadidiR.TomlinsonI.et al (2015). FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. Oncotarget6 (11), 9240–9256. 10.18632/oncotarget.3284
79
LiY.MaC.ZhouT.LiuY.SunL.YuZ. (2016). TRIM65 negatively regulates p53 through ubiquitination. Biochem. biophysical Res. Commun.473 (1), 278–282. 10.1016/j.bbrc.2016.03.093
80
LiY. Y.WuC.ShahS. S.ChenS. M.WangpaichitrM.KuoM. T.et al (2017). Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation. Mol. Oncol.11 (12), 1806–1825. 10.1002/1878-0261.12151
81
LiangQ.TangC.TangM.ZhangQ.GaoY.GeZ. (2019). TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. J. Exp. Clin. Cancer Res.38 (1), 159. 10.1186/s13046-019-1143-x
82
LinJ. H.YamazakiM. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet.42 (1), 59–98. 10.2165/00003088-200342010-00003
83
LiuC.LouW.YangJ. C.LiuL.GaoA. C. (2018). Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat. Commun.9 (1). 4700. 10.1038/s41467-018-07178-x
84
LiuM. L.ZangF.ZhangS. J. (2019). RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC). Biomed. Pharmacother.118, 109250. 10.1016/j.biopha.2019.109250
85
LiuT.XiongJ.YiS.ZhangH.ZhouS.GuL.et al (2017). FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene36 (12), 1678–1686. 10.1038/onc.2016.331
86
LongL.XiangH.LiuJ.ZhangZ.SunL. (2019). ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells. Exp. Mol. Pathol.106, 116–122. 10.1016/j.yexmp.2019.01.001
87
LongleyD. B.HarkinD. P.JohnstonP. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer3 (5), 330–338. 10.1038/nrc1074
88
LuY.HanD.LiuW.HuangR.OuJ.ChenX.et al (2018). RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. Cancer Biol. Ther.19 (12), 1128–1138. 10.1080/15384047.2018.1480293
89
LukenbillJ.KalaycioM. (2013). Fludarabine: a review of the clear benefits and potential harms. Leuk. Res.37 (9), 986–994. 10.1016/j.leukres.2013.05.004
90
MalekE.Abdel-MalekM. A.JagannathanS.VadN.KarnsR.JeggaA. G.et al (2017). Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia31 (3), 645–653. 10.1038/leu.2016.258
91
MarzioA.PucciniJ.KwonY.MaverakisN. K.ArbiniA.SungP.et al (2019). The F-box domain-dependent activity of EMI1 regulates PARPi sensitivity in triple-negative breast cancers. Mol. Cel.73 (2), 224–237. 10.1016/j.molcel.2018.11.003.e6
92
MiniE.NobiliS.CaciagliB.LandiniI.MazzeiT. (2006). Cellular pharmacology of gemcitabine. Ann. Oncol.17 (Suppl. 5), v7–12. 10.1093/annonc/mdj941
93
MunG. I.ChoiE.LeeY.LeeY. S. (2020). Decreased expression of FBXW7 by ERK1/2 activation in drug-resistant cancer cells confers transcriptional activation of MDR1 by suppression of ubiquitin degradation of HSF1. Cel Death Dis.11 (5), 395. 10.1038/s41419-020-2600-3
94
MuscoliniM.MontagniE.PalermoV.Di AgostinoS.GuW.Abdelmoula-SouissiS.et al (2011). The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J. Biol. Chem.286 (46), 39693–39702. 10.1074/jbc.M111.279539
95
NalepaG.RolfeM.HarperJ. W. (2006). Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov.5 (7), 596–613. 10.1038/nrd2056
96
NingY.HuiN.QingB.ZhuoY.SunW.DuY.et al (2019). ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation. Cel Death Dis.10 (6), 414. 10.1038/s41419-019-1635-9
97
NunesJ.ZhangH.AngelopoulosN.ChhetriJ.OsipoC.GrotheyA.et al (2016). ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget7 (19), 27599–27612. 10.18632/oncotarget.8504
98
O'BrienP. M.DaviesM. J.ScurryJ. P.SmithA. N.BartonC. A.HendersonM. J.et al (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br. J. Cancer98 (6), 1085–1093. 10.1038/sj.bjc.6604281
99
OnoratiA. V.DyczynskiM.OjhaR.AmaravadiR. K. (2018). Targeting autophagy in cancer. Cancer124 (16), 3307–3318. 10.1002/cncr.31335
100
PanC.ChunJ.LiD.BoeseA. C.LiJ.KangJ.et al (2019). Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J. Clin. Invest.129 (10), 4110–4123. 10.1172/jci125963
101
PanX.ChenY.ShenY.TantaiJ. (2019). Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7. Cel Death Dis.10 (6), 429. 10.1038/s41419-019-1660-8
102
PandyaK.WyattD.GallagherB.ShahD.BakerA.BloodworthJ.et al (2016). PKCα attenuates jagged-1-mediated Notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance. Clin. Cancer Res. : official J. Am. Assoc. Cancer Res.22 (1), 175–186. 10.1158/1078-0432.Ccr-15-0179
103
ParkJ.BaeE. K.LeeC.ChoiJ. H.JungW. J.AhnK. S.et al (2014). Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep.47 (5), 274–279. 10.5483/bmbrep.2014.47.5.134
104
Perez-LosadaJ.MaoJ. H.BalmainA. (2005). Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res.65 (15), 6488–6492. 10.1158/0008-5472.Can-05-1294
105
PokharelY. R.KimN. D.HanH. K.OhW. K.KangK. W. (2010). Increased ubiquitination of multidrug resistance 1 by ginsenoside Rd. Nutr. Cancer62 (2), 252–259. 10.1080/01635580903407171
106
QinX.ChenS.QiuZ.ZhangY.QiuF. (2012). Proteomic analysis of ubiquitination-associated proteins in a cisplatin-resistant human lung adenocarcinoma cell line. Int. J. Mol. Med.29 (5), 791–800. 10.3892/ijmm.2012.912
107
QinY.CuiH.ZhangH. (2016). Overexpression of TRIM25 in lung cancer regulates tumor cell progression. Techn. Cancer Res. Treat.15 (5), 707–715. 10.1177/1533034615595903
108
QuC.KunkallaK.VaghefiA.FrederiksenJ. K.LiuY.ChapmanJ. R.et al (2018). Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Lett.436, 149–158. 10.1016/j.canlet.2018.08.020
109
RavindranathA. K.KaurS.WernyjR. P.KumaranM. N.Miletti-GonzalezK. E.ChanR.et al (2015). CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget6 (28), 26308–26321. 10.18632/oncotarget.4763
110
ReutherC.HeinzleV.NöltingS.HerterichS.HahnerS.HalilovicE.et al (2018). The HDM2 (MDM2) inhibitor NVP-CGM097 inhibits tumor cell proliferation and shows additive effects with 5-fluorouracil on the p53-p21-Rb-E2F1 cascade in the p53wild type neuroendocrine tumor cell line GOT1. Neuroendocrinology106 (1), 1–19. 10.1159/000453369
111
RuY.WangQ.LiuX.ZhangM.ZhongD.YeM.et al (2016). The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL. Scientific Rep.6, 28352. 10.1038/srep28352
112
RulinaA. V.MittlerF.ObeidP.GerbaudS.GuyonL.SulpiceE.et al (2016). Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity. Cel Death Dis.7 (12), e2505. 10.1038/cddis.2016.395
113
SakamotoK. M.KimK. B.KumagaiA.MercurioF.CrewsC. M.DeshaiesR. J. (2001). Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. United States America98 (15), 8554–8559. 10.1073/pnas.141230798
114
SchneppP. M.ShelleyG.DaiJ.WakimN.JiangH.MizokamiA.et al (2020). Single-cell transcriptomics analysis identifies nuclear protein 1 as a regulator of docetaxel resistance in prostate cancer cells. Mol. Cancer Res. : MCR18 (9), 1290–1301. 10.1158/1541-7786.Mcr-20-0051
115
ScottK.HaydenP. J.WillA.WheatleyK.CoyneI. (2016). Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst. Rev.4, Cd010816. 10.1002/14651858.CD010816.pub2
116
SenftD.QiJ.RonaiZ. A. (2018). Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer18 (2), 69–88. 10.1038/nrc.2017.105
117
ShenY.SunY.ZhangL.LiuH. (2017). Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells. Tumour Biol. : J. Int. Soc. Oncodevelopmental Biol. Med.39 (6), 1010428317703941. 10.1177/1010428317703941
118
ShengW.DongM.ChenC.WangZ.LiY.WangK.et al (2017). Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. FASEB J. : official Publ. Fed. Am. Societies Exp. Biol.31 (6), 2429–2438. 10.1096/fj.201601240R
119
ShiJ.ZhangW.YouM.XuY.HouY.JinJ. (2016). Pioglitazone inhibits EGFR/MDM2 signaling-mediated PPARγ degradation. Eur. J. Pharmacol.791, 316–321. 10.1016/j.ejphar.2016.09.010
120
ShiQ.ZhuY.MaJ.ChangK.DingD.BaiY.et al (2019). Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Mol. Cancer18 (1), 170. 10.1186/s12943-019-1096-x
121
ShimizuH.TakeishiS.NakatsumiH.NakayamaK. I. (2019). Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells. JCI Insight4 (4). 10.1172/jci.insight.125138
122
SiegelR. L.MillerK. D.JemalA. (2019). Cancer statistics. CA: a Cancer J. clinicians69 (1), 7–34. 10.3322/caac.21551
123
SkaarJ. R.PaganJ. K.PaganoM. (2014). SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov.13 (12), 889–903. 10.1038/nrd4432
124
SmithP. G.TanakaH.ChantryA. (2012). A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells. Oncotarget3 (5), 518–524. 10.18632/oncotarget.500
125
SongY.ZhouX.BaiW.MaX. (2015). FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. Tumour Biol. : J. Int. Soc. Oncodevelopmental Biol. Med.36 (6), 4197–4202. 10.1007/s13277-015-3056-4
126
SuJ. L.ChengX.YamaguchiH.ChangY. W.HouC. F.LeeD. F.et al (2011). FOXO3a-Dependent mechanism of e1a-induced chemosensitization. Cancer Res.71 (21), 6878–6887. 10.1158/0008-5472.Can-11-0295
127
TanakaN.KosakaT.MiyazakiY.MikamiS.NiwaN.OtsukaY.et al (2016).Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation. JCI Insight1 (18), e83654. 10.1172/jci.insight.83654
128
TangD. E.DaiY.LinL. W.XuY.LiuD. Z.HongX. P.et al (2019). STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling. Cancer Sci.110 (10), 3145–3156. 10.1111/cas.14166
129
TangD. E.DaiY.XuY.LinL. W.LiuD. Z.HongX. P.et al (2020). The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization. Carcinogenesis41 (1), 56–66. 10.1093/carcin/bgz085
130
TathamM. H.PlechanovováA.JaffrayE. G.SalmenH.HayR. T. (2013). Ube2W conjugates ubiquitin to α-amino groups of protein N-termini. Biochem. J.453 (1), 137–145. 10.1042/bj20130244
131
TianH. L.YuT.XuN. N.FengC.ZhouL. Y.LuoH. W.et al (2010). A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway. Cancer Lett.297 (1), 18–30. 10.1016/j.canlet.2010.04.020
132
TongJ.TanS.ZouF.YuJ.ZhangL. (2017). FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene36 (6), 787–796. 10.1038/onc.2016.247
133
TsuchiyaM.NakajimaY.WakuT.HiyoshiH.MorishitaT.FurumaiR.et al (2015). CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population. Oncogene34 (35), 4656–4663. 10.1038/onc.2014.387
134
UchidaC.KitagawaM. (2016). RING-, HECT-, and RBR-type E3 ubiquitin ligases: involvement in human cancer. Curr. Cancer Drug Targets16 (2), 157–174. 10.2174/1568009616666151112122801
135
VasanN.BaselgaJ.HymanD. M. (2019). A view on drug resistance in cancer. Nature575 (7782), 299–309. 10.1038/s41586-019-1730-1
136
VuB.WovkulichP.PizzolatoG.LoveyA.DingQ.JiangN.et al (2013). Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett.4 (5), 466–469. 10.1021/ml4000657
137
WaksA. G.WinerE. P. (2019). Breast cancer treatment: a review. Jama321 (3), 288–300. 10.1001/jama.2018.19323
138
WangD.MaL.WangB.LiuJ.WeiW. (2017). E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev.36 (4), 683–702. 10.1007/s10555-017-9703-z
139
WangH.LiuB.ZhangC.PengG.LiuM.LiD.et al (2009). Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J. Pathol.218 (1), 76–85. 10.1002/path.2512
140
WangH.LuB.CastilloJ.ZhangY.YangZ.McAllisterG.et al (2016). Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) inhibition via stabilizing angiomotins and inhibiting YAP signaling. J. Biol. Chem.291 (29), 15256–15266. 10.1074/jbc.M116.722967
141
WangX.RusinA.WalkeyC. J.LinJ. J.JohnsonD. L. (2019). The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates drug resistance and apoptosis. J. Biol. Chem.294. 19255-19268. 10.1074/jbc.RA119.008849
142
WangY.GuoA.LiangX.LiM.ShiM.LiY.et al (2017). HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation. Oncotarget8 (14), 23564–23574. 10.18632/oncotarget.15797
143
WuB.LiuZ. Y.CuiJ.YangX. M.JingL.ZhouY.et al (2017). F-box protein FBXO22 mediates polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int. J. Mol. Sci.18 (1). 10.3390/ijms18010212
144
WuC.ChenL.TaoH.KongL.HuY. (2020). Ring finger protein 38 induces the drug resistance of cisplatin in non-small cell lung cancer. Cel Biol. Int.10.1002/cbin.11423
145
X CheX.ZhangY.QuX.GuoT.MaY.LiC.et al (2017). The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells. Neoplasma64 (6), 887–892. 10.4149/neo_2017_610
146
XiaoQ.YangY.AnQ.QiY. (2017). MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2. Oncotarget8 (21), 34678–34686. 10.18632/oncotarget.16149
147
XuL.ZhangY.QuX.CheX.GuoT.CaiY.et al (2017).E3 ubiquitin ligase cbl-b prevents tumor metastasis by maintaining the epithelial phenotype in multiple drug-resistant gastric and breast cancer cells. Neoplasia, 19 (4). New York, NY, 374–382. 10.1016/j.neo.2017.01.011
148
YanS. C.LiuY. P.ZhangL. Y.QuJ. L.XuL.LiuJ.et al (2011). Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals. Acta Oncol.50 (5), 693–699. 10.3109/0284186x.2010.543144
149
YangY.LuY.WangL.MizokamiA.KellerE. T.ZhangJ.et al (2016). Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncol. Rep.36 (1), 559–566. 10.3892/or.2016.4809
150
YinH.ZhuQ.LiuM.TuG.LiQ.YuanJ.et al (2017). GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis. Int. J. Oncol.51 (4), 1191–1198. 10.3892/ijo.2017.4117
151
YinY.XieC. M.LiH.TanM.SunY. (2019). The FBXW2–MSX2–SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc. Natl. Acad. ences116 (41), 201905973.
152
YokoboriT.YokoyamaY.MogiA.EndohH.AltanB.KosakaT.et al (2014). FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol. Cancer Res. : MCR12 (1), 32–37. 10.1158/1541-7786.Mcr-13-0341
153
YuC.ChenS.GuoY.SunC. (2018). Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. Theranostics8 (12), 3224–3236. 10.7150/thno.23259
154
YuH. G.WeiW.XiaL. H.HanW. L.ZhaoP.WuS. J.et al (2013). FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells. Asian Pac. J. Cancer Prev. : APJCP14 (11), 6321–6326. 10.7314/apjcp.2013.14.11.6321
155
YuJ. J.ZhouD. D.YangX. X.CuiB.TanF. W.WangJ.et al (2020). TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nat. Commun.11 (1), 3660. 10.1038/s41467-020-17385-0
156
YuP.FanY.QuX.ZhangJ.SongN.LiuJ.et al (2016). Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells. J. BUON : official J. Balkan Union Oncol.21 (4), 867–873.
157
YuX.WangR.ZhangY.ZhouL.WangW.LiuH.et al (2019). Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin. Oncogene38 (50), 7457–7472. 10.1038/s41388-019-0955-7
158
ZhangP. F.ShengL. L.WangG.TianM.ZhuL. Y.ZhangR.et al (2016). miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget7 (23), 35284–35292. 10.18632/oncotarget.9169
159
ZhangR.LiS. W.LiuL.YangJ.HuangG.SangY. (2020). TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis9 (5), 45. 10.1038/s41389-020-0229-9
160
ZhangW. L.ZhangJ. H.WuX. Z.YanT.LvW. (2015). miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. Int. J. Oncol.47 (3), 1043–1053. 10.3892/ijo.2015.3076
161
ZhangX.LeeH. C.ShiraziF.BaladandayuthapaniV.LinH.KuiatseI.et al (2018). Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia32 (10), 2224–2239. 10.1038/s41375-018-0044-x
162
ZhangX.LiC. F.ZhangL.WuC. Y.HanL.JinG.et al (2016). TRAF6 restricts p53 mitochondrial translocation, apoptosis, and tumor suppression. Mol. Cel.64 (4), 803–814. 10.1016/j.molcel.2016.10.002
163
ZhangY.QuX.TengY.LiZ.XuL.LiuJ.et al (2015). Cbl-b inhibits P-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers. Oncotarget6 (9), 6737–6748. 10.18632/oncotarget.3253
164
ZhangZ.WuJ. Y.HaitW. N.YangJ. M. (2004). Regulation of the stability of P-glycoprotein by ubiquitination. Mol. Pharmacol.66 (3), 395. 10.1124/mol.104.001966
165
ZhaoL.QiuT.JiangD.XuH.ZouL.YangQ.et al (2020). SGCE promotes breast cancer stem cells by stabilizing EGFR. Adv. Sci. (Weinh)7 (14), 1903700. 10.1002/advs.201903700
166
ZhengN.ShabekN. (2017). Ubiquitin ligases: structure, function, and regulation. Annu. Rev. Biochem.86, 129–157. 10.1146/annurev-biochem-060815-014922
Summary
Keywords
E3 ubiquitin ligase, cancer, cancer treatment, drugresistance, drug
Citation
Liu Y, Duan C and Zhang C (2021) E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential. Front. Pharmacol. 12:645864. doi: 10.3389/fphar.2021.645864
Received
24 December 2020
Accepted
24 February 2021
Published
15 April 2021
Volume
12 - 2021
Edited by
Dexin Kong, Tianjin Medical University, China
Reviewed by
Pranav Gupta, Albert Einstein College of Medicine, United States
Xiuping Yu, Louisiana State University Health Shreveport, United States
Updates
Copyright
© 2021 Liu, Duan and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chaojun Duan, duancjxy@126.com; Chunfang Zhang, zcf6169@outlook.com
† These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.